Mounjaro and Your Pancreas: Making Sense of the Risk

What the MHRA actually said, and what it means for you

In January 2026, the MHRA published a Drug Safety Update specifically addressing acute pancreatitis in people using GLP-1 medicines, which includes tirzepatide. The regulator's position is precise: pancreatitis is a known, infrequent risk, not a common one. That distinction matters. It means the risk is real enough to require monitoring and patient awareness, but it does not appear frequently enough to disqualify most people from treatment.

The pancreas-and-Mounjaro concern is not new. GLP-1 receptors are expressed in pancreatic tissue, and regulators have watched this signal across the entire class since semaglutide and liraglutide were first approved. Clinical trial data, including the SURMOUNT programme involving thousands of adults taking tirzepatide, found pancreatitis rates that were low and broadly consistent with background rates in people with obesity. The NHS medicines guidance for tirzepatide reflects this: pancreatitis is listed, explained, and flagged as something to watch for rather than something that makes the medicine unsuitable for most candidates.

If you want to read the clinical detail yourself, the NHS tirzepatide medicines page covers the side-effect profile clearly, and the full prescribing information is available through the electronic Medicines Compendium. Our clinical team page gives you a sense of how our prescribers approach this assessment.

When stomach pain is the signal that needs urgent attention

Most gastrointestinal side effects on tirzepatide are mild and tend to cluster in the first few weeks or after a dose increase. Nausea, loose stools, indigestion and reduced appetite are common and usually settle. Pancreatitis feels different, and that difference is the thing worth knowing before you start.

The characteristic presentation is severe abdominal pain that does not ease, often felt in the upper abdomen and radiating into the back. Vomiting may accompany it, but the pain can occur without it. It tends to be persistent rather than cramping. If you experience that pattern, the guidance from both the MHRA and the NHS is consistent: stop eating and drinking and seek urgent medical help. Do not wait to see if it passes.

A practical checking habit that takes under a minute: each time you press your abdomen gently after a dose and feel the normal mild tenderness some people get, note whether it resolves over an hour or intensifies. Intensifying, spreading or back-radiating pain is the trigger to call 999 or go to A&E, not to monitor further at home. You can read more about what warning symptoms look like in the context of Mounjaro-related pancreatic symptoms.

For a broader picture of how tirzepatide affects the pancreas mechanistically, the tirzepatide and pancreas page covers the biology in more depth.

Who carries a higher baseline risk, and what that means for the consultation

The decision about whether tirzepatide is right for you is shaped partly by what is already in your medical history. A personal history of pancreatitis is a significant factor: anyone who has had an episode before is at elevated risk of recurrence, and prescribers weigh this carefully. Gallstones are another relevant factor, because gallbladder disease is itself a risk factor for pancreatitis, and GLP-1 medicines can influence gallbladder function. Alcohol use, hypertriglyceridaemia and certain inherited metabolic conditions also affect baseline risk.

This is exactly the territory a proper clinical consultation should cover. At nume, a GPhC-registered prescriber reads your consultation answers the same day, not software making an automated pass, but a qualified clinician who can identify these flags. If there is a relevant history, they may ask follow-up questions or conclude that treatment is not appropriate for you right now. That outcome, while disappointing, is the system working correctly.

You can explore whether Mounjaro can damage the pancreas in more detail, or read about Mounjaro's broader side-effect profile to put the pancreatic risk in its full context alongside more common GI effects like persistent diarrhoea. If you would like to understand what Mounjaro is and how it works before returning to the safety questions, the Mounjaro overview page is a good starting point.

Reporting a reaction and what to do next

If you experience anything that concerns you on tirzepatide, you have two immediate routes. For symptoms that suggest pancreatitis (or any severe, unexpected reaction) the NHS urgent care system comes first: 999 for an emergency, 111 if you need guidance on whether to attend A&E. Tell the clinician you are taking tirzepatide and when you last injected.

After any urgent episode, suspected side effects can be reported directly to the MHRA using the Yellow Card scheme. Patients can submit reports themselves; you do not need to go through a doctor. These reports contribute directly to post-market safety surveillance and are how regulators track signals in real-world populations. The January 2026 Drug Safety Update on pancreatitis is itself a product of that ongoing monitoring process.

For non-urgent concerns, our prescribers are available seven days a week through aftercare. If you are thinking about starting treatment and want to discuss your history first, our free consultation is the place to do that. There is no pressure and no assumption of suitability; the conversation exists precisely to work out whether treatment is right for you.